[an error occurred while processing this directive] | [an error occurred while processing this directive]
Expert consensus on the treatment of metastasis nasopharyngeal carcinoma
Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association, Chen Xiaozhong, Li Jingao, Lin Shaojun, Hu Chaosu
Department of Radiation Oncology,Zhejian Cancer Hospital,Hangzhou 310022,China (Chen XZ); Department of Radiation Oncology,Jiangxi Cancer Hospital,Nanchang 330029,China (Li JG); Department of Radiation Oncology,Fujian Cancer Hospital,Fuzhou 350005,China (Lin SJ); Department of Radiation Oncology,Cancer Hospital,Fuda University,Shanghai 200032,China (Hu CS)
Abstract As the application of intensity modulated-radiotherapy and improvement of local control about nasopharyngeal carcinoma,metastases have been an urgent problem needed to be solved. Due to the great heterogeneities of metastasis NPC,the treatment strategies and prognoses are very different. At present,no treatment guideline has been achieved in this field. This consensus tries to give some directions on the treatment of metastasis NPC.We discuss and summarize treatment models for the metastases at first diagnosis,after radical treatment and after failure of platinum-based chemotherapy respectively by reviewing relevant literatures and clinical trials. For some clinically significant problems without enough supports of clinical data,we draft out it according clinical experiences of experts,in order to reach a consensus about the best treatment strategies for metastasis nasopharyngeal carcinoma.
Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association,Chen Xiaozhong,Li Jingao et al. Expert consensus on the treatment of metastasis nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(1): 23-28.
Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association,Chen Xiaozhong,Li Jingao et al. Expert consensus on the treatment of metastasis nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(1): 23-28.
[1] Jiang F,Jin T,Feng X L,et al. Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era:the Zhejiang Cancer Hospital′s experience[J].J Cancer Res Ther,2015,11(6):179-184.DOI:10.4103/0973-1482.168181 [2] Ou XM,Zhou X,Shi Q,et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy:new insight into the value of total dose of cisplatin and radiation boost[J].Oncotarget,2015,6(35):38381-38397.DOI:10.18632/oncotarget.5420 [3] Lee AWM,Ng WT,Chan LLK,et al. Evolution of treatment for nasopharyngeal cancer–success and setback in the intensity-modulated radiotherapy era[J].Radiother Oncol,2014,110(3):377-384.DOI:10.1016/j.radonc.2014.02.003 [4] Lang JY,Gao L,Guo Y,et al. Comprehensive treatment of squamous cell cancer of head and neck:Chinese expert consensus 2013[J].Future Oncol,2014,10(9):1635-1648 [5] Chua MLK,Wee JTS,Hui EP,et al. Nasopharyngeal carcinoma[J].Lancet,2016,387(10022):1012-1024.DOI:10.1016/S0140-6736(15)00055-0 [6] Lee AWM,Ng WT,Chan LK,et al. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement[J].Oral Oncol,2012,48(10):1007-1013.DOI:10.1016/j.oraloncology.2012.03.022 [7] Lee V,Kwong D,Leung TW,et al. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma–How far have we achieved?[J].Crit Rev OncolHematol,2017,114:13-23.DOI:10.1016/j.critrevonc.2017.03.030 [8] Au E,Ang PT.A phase Ⅱ trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma[J].Ann Oncol,1994,5(1):87-89.DOI:10.1093/oxfordjournals.annonc.a058703 [9] Chi KH,Chan WK,Cooper DL,et al. A phase Ⅱ study of outpatient chemotherapy with cisplatin,5-fluorouracil,and leucovorin in nasopharyngeal carcinoma[J].Cancer,1994,73(2):247-252.DOI:10.1002/1097-0142(19940115)73:2<247::AID-CNCR2820730203>3.0.CO;2-7 [10] Peng PJ,Ou XQ,Liao H,et al. Phase Ⅱ study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy[J].Ther Adv Med Oncol,2016,8(3):153-159.DOI:10.1177/1758834016637592 [11] Chua DTT,Sham JST,Au GKH.A phase Ⅱ study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma[J].Oral Oncol,2005,41(6):589-595.DOI:10.1016/j.oraloncology.2005.01.008 [12] Li W,Bai YT,Wu M,et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver:propensity score matching analysis[J].Oncotarget,2017,8(32):52132-52141.DOI:10.18632/oncotarget.10383 [13] 田允铭,韩非,曾雷,等.寡转移状态下初治鼻咽癌的预后及治疗模式探讨[J].中华放射肿瘤学杂志,2016,25(11):1156-1160.DOI:10.3760/cma.j.issn.1004-4221.2016.11.003.Tian YM,Han F,Zeng L,et al. Prognosis and treatment of newly diagnosed nasopharyngeal carcinoma with oligometastases[J].Chin J Radiat Oncol,2016,25(11):1156-1160.DOI:10.3760/cma.j.issn.1004-4221.2016.11.003 [14] Hu SX,He XH,Dong M,et al. Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis[J].Med Oncol,2015,32(9):224.DOI:10.1007/s12032-015-0663-2.[15] Zeng L,Tian YM,Huang Y,et al. Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis:therapeutic approaches and prognostic factors[J].PLoS One,2014,9(9):e108070.DOI:10.1371/journal.pone.0108070 [16] 汪琛,李金高,邹嵩,等.初治转移性鼻咽癌预后因素及治疗模式探讨[J].中山大学学报(医学科学版),2014,35(6):880-888.DOI:10.13471/j.cnki.j.sun.yat-sen.univ (med.sci).2014.0146.Wang S,Li JG,Zou S,et al. The early cure metastatic prognostic factors and treatment of nasopharyngeal carcinoma (NPC) model discussed[J].J Sun Yat-sen Univ (Med Sci),2014,35(6):880-888.DOI:10.13471/j.cnki.j.sun.yat-sen.univ (med.sci).2014.0146 [17] Chen MY,Jiang R,Guo L,et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis[J].Chin J Cancer,2013,32(11):604-613.DOI:10.5732/cjc.013.10148 [18] Tian YH,Zou WH,Xiao WW,et al. Oligometastases in AJCC stage ⅠVc nasopharyngeal carcinoma:a subset with betteroverall survival[J].Head Neck,2016,38(8):1152-1157.DOI:10.1002/hed.24345 [19] Rusthoven CG,Lanning RM,Jones BL,et al. Metastatic nasopharyngeal carcinoma:patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy[J].RadiotherOncol,2017,124(1):139-146.DOI:10.1016/j.radonc.2017.03.019 [20] Hu JY,Kong L,Gao J,et al. Use of radiation therapy in metastatic nasopharyngeal cancer improves survival:a SEER analysis[J].Sci Rep,2017,7(1):721.DOI:10.1038/s41598-017-00655-1 [21] Zou X,You R,Liu H,et al. Establishment and validation of M1 stage subdivisions forde novometastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment[J].Eur J Cancer,2017,77:117-126.DOI:10.1016/j.ejca.2017.02.029 [22] Jiang R,You R,Pei XQ,et al. Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients′ survival[J].Oncotarget,2016,7(3):3645-3657.DOI:10.18632/oncotarget.6436 [23] 蓝玉宏,田允铭,白力,等.初治转移鼻咽癌疗后预后评分模型建立及分层治疗研究[J].中华放射肿瘤学杂志,2015,24(4):421-426.DOI:10.3760/cma.j.issn.1004-4221.2015.04.017.Lan YH,Tian YM,Bai L,et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2015,24(4):421-426.DOI:10.3760/cma.j.issn.1004-4221.2015.04.017 [24] Liang Y,Bu JG,Cheng JL,et al. Selective radiotherapy after distant metastasis of nasopharyngeal carcinoma treated with dose-dense Cisplatin plus Fluorouracil[J].Asian Pac J Cancer Prev,2015,16(14):6011-6017.DOI:10.7314/APJCP.2015.16.14.6011 [25] Golden EB,Chhabra A,Chachoua A,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial[J].Lancet Oncol,2015,16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6 [26] Lin SJ,Tham IWK,Pan JJ,et al. Combined high-dose radiation therapy and systemic chemotherapy improves survivalin patients with newly diagnosed metastatic nasopharyngeal cancer[J].Am J Clin Oncol,2012,35(5):474-479.DOI:10.1097/COC.0b013e31821a9452 [27] Weichselbaum RR,Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol,2011,8(6):378-382.DOI:10.1038/nrclinonc.2011.44 [28] Hellman S,Weichselbaum RR.Oligometastases[J].J Clin Oncol,1995,13(1):8-10.DOI:10.1200/JCO.1995.13.1.8 [29] Fong YM,Fortner J,Sun RL,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases[J].Ann Surg,1999,230(3):309-321.DOI:10.1097/00000658-199909000-00004 [30] Pastorino U,Buyse M,Friedel G,et al. Long-term results of lung metastasectomy:prognostic analyses based on 5206 cases[J].J Thorac Cardiovasc Surg,1997,113(1):37-49.DOI:10.1016/S0022-5223(97)70397-0 [31] Huang J,Li QJ,Zheng Y,et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma:a comparative study and review of the literature[J].BMC Cancer,2014,14:818.DOI:10.1186/1471-2407-14-818 [32] Shen LJ,Dong J,Li S,et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasisof nasopharyngeal carcinoma[J].Oncologist,2015,20(3):291-298.DOI:10.1634/theoncologist.2014-0206 [33] Pan CC,Wu PH,Yu JR,et al. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation[J].Eur J Radiol,2012,81(4):e473-e477.DOI:10.1016/j.ejrad.2011.05.037 [34] Zhang L,Huang Y,Hong SD,et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre,randomised,open-label,phase 3 trial[J].Lancet,2016,388(10054):1883-1892.DOI:10.1016/S0140-6736(16)31388-5 [35] Zheng W,Zong JF,Huang CB,et al. Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status[J].PLoS One,2016,11(1):e0146771.DOI:10.1371/journal.pone.0146771 [36] Ma J,Wen ZS,Lin P,et al. The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma:a retrospective study of 105 cases[J].Chin J Cancer,2010,29(9):787-795.DOI:10.5732/cjc.010.10098 [37] Jin Y,Cai YC,Cao Y,et al. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes[J].J Surg Oncol,2012,106(3):322-326.DOI:10.1002/jso.23034 [38] Lu TZ,Guo QJ,Cui XF,et al. Prognostic evaluation of nasopharyngeal carcinoma with bone-only metastasis after therapy[J].Yonsei Med J,2016,57(4):840-845.DOI:10.3349/ymj.2016.57.4.840 [39] Leong SS,Wee J,Rajan S,et al. Triplet combination of gemcitabine,paclitaxel,and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma[J].Cancer,2008,113(6):1332-1337.DOI:10.1002/cncr.23687 [40] Hong RL,Sheen TS,Ko JY,et al. Induction with mitomycin C,doxorubicin,cisplatin and maintenance with weekly 5-fluorouracil,leucovorin for treatment of metastatic nasopharyngeal carcinoma:a phase Ⅱ study[J].Br J Cancer,1999,80(12):1962-1967.DOI:10.1038/sj.bjc.6690627 [41] Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastriccancer (SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.DOI:10.1016/S1470-2045(08)70035-4 [42] Yokota T,Onozawa Y,Boku N,et al. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy[J].Jpn J Clin Oncol,2011,41(12):1351-1357.DOI:10.1093/jjco/hyr147 [43] Kim HS,Kim HR,Kim GM,et al. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma[J].Cancer Chemother Pharmacol,2012,70(4):539-546.DOI:10.1007/s00280-012-1933-8 [44] You B,Le Tourneau C,Chen EX,et al. A phase Ⅱ trial of Erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma[J].Am J Clin Oncol,2012,35(3):255-260.DOI:10.1097/COC.0b013e31820 dbdcc [45] Xue C,Huang Y,Huang PY,et al. Phase Ⅱ study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma[J].Ann Oncol,2013,24(4):1055-1061.DOI:10.1093/annonc/mds581 [46] Ma BBY,Poon TCW,To KF,et al. Prognostic significance of tumor angiogenesis,Ki 67,p53 oncoprotein,epidermalgrowth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study[J].Head Neck,2003,25(10):864-872.DOI:10.1002/hed.10307 [47] Vermorken JB,Mesia R,Rivera F,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J].N Engl J Med,2008,359(11):1116-1127.DOI:10.1056/NEJMoa0802656 [48] Xu TT,Ou XM,Shen CY,et al. Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma[J].Anti-Cancer Drugs,2016,27(1):66-70.DOI:10.1097/CAD.0000000000000294 [49] Elser C,Siu LL,Winquist E,et al. Phase Ⅱ trial of Sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma[J].J Clin Oncol,2007,25(24):3766-3773.DOI:10.1200/JCO.2006.10.2871 [50] Jin T,Li B,Chen XZ.A phase Ⅱ trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)[J].Oncol Res,2013,21(6):317-323.DOI:10.3727/096504014X13983417587401 [51] Peng PJ,Cheng H,Ou XQ,et al. Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy:multi-institutional retrospective analysis[J].Drug Des,Devel Ther,2014,8:1083-1087.DOI:10.2147/DDDT.S67592 [52] Chua DTT,Sham JST,Au GKH.A phase Ⅱ study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy[J].Oral Oncol,2003,39(4):361-366.DOI:10.1016/S1368-8375(02)00120-3 [53] Peng PJ,Lv BJ,Wang ZH,et al. Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens[J].Ther Adv Med Oncol,2017,9(2):68-74.DOI:10.1177/1758834016675099 [54] Leong SS,Wee J,Tay MH,et al. Paclitaxel,carboplatin,and gemcitabine in metastatic nasopharyngeal carcinoma:a Phase Ⅱ trial using a triplet combination[J].Cancer,2005,103(3):569-575.DOI:10.1002/cncr.20804 [55] Chan ATC,Hsu MM,Goh BC,et al. Multicenter,phase Ⅱ study of Cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J].J Clin Oncol,2005,23(15):3568-3576.DOI:10.1200/JCO.2005.02.147 [56] Hsu C,Lee SH,Ejadi S,et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma:results of the KEYNOTE-028 study[J].J Clin Oncol,2017.DOI:10.1200/JCO.2017.73.3675 [57] Shen LJ,Chen C,Li BF,et al. High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse:a retrospective analysis of 2433 cases[J].PLoS One,2013,8(7):e68660.DOI:10.1371/journal.pone.0068660 [58] Huang PY,Wang CT,Cao KJ,et al. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy:findings from a randomised trial[J].Eur J Cancer,2013,49(8):1923-1931.DOI:10.1016/j.ejca.2013.01.027
2018, Vol. 27 
